Champions Oncology Growth, Revenue, Number of Employees and Funding

Overview

Location:
Hackensack, NJ USA
Total Funding:$36.8M
Industry:Biotech
Founded:2007
Lead Investor(s):National Securities Corporation
Press

Industry Ranking

State Ranking

Growjo 10k Ranking

Revenue & Financials

  • Champions Oncology's revenue is currently $20.2M per year.
  • Champions Oncology received $5.2M in venture funding in June 2016.
  • Champions Oncology's revenue per employee is $194625
  • Champions Oncology's total funding is $36.8M.

Employee Data

  • Champions Oncology has 104 Employees.
  • Champions Oncology grew their employee count by 16% last year.
  • Champions Oncology currently has 21 job openings.

What Is Champions Oncology?

Champions Oncology, Inc. provides an end-to-end range of research and development solutions and services that improve the productivity of oncology drug development. Using both in vitro to in vivo testing platforms companies can leverage the expertise at Champions Oncology to help guide decision making for clinical development scenarios. From screens using commercially-available and custom cell lines, to studies leveraging syngeneic or traditional patient-derived studies xenograft (PDX) models, and modeling treatment response in the clinic, Champions Oncology is your partner in meeting today's needs and innovating for tomorrow's challenges. At the core of our services is the Champions TumorGraft® (CTG) platform, a comprehensive, unique compendium of PDX models that preserve the biological characteristics of human tumors and are highly predictive of clinical outcomes. Services utilizing Champions TumorGrafts® PDX tumor models include evaluating tumor sensitivity/resistance to various single, combination, standard and novel chemotherapy agents, biomarker discovery and the identification of novel drug combinations. Champions TumorGraft® PDX models are procured through agreements our Clinical Collaboration Network, a series of renowned oncology institutions in the US and around the world, as well as through the company's Personalized Oncology Solutions business. Personalized Oncology Solutions assist clinical oncologists by establishing and administering expert tumor panels for their patients to analyze medical records and test results, to assist in understanding conventional and experimental options and to identify and arrange for testing, analysis and study of the patients cancer tissues, as appropriate. Additionally, the company offers personalized PDX development, drug studies and genome sequencing, whereby physicians evaluate the effects of cancer drugs and understand the genetic makeup of each patient's tumor, enabling them to better select treatment regimens.

keywords:Biotechnology,Enterprise Software,Health It,Healthcare,Pharmaceuticals

104

Number of Employees

$20.2M

Revenue (est)

21

Current Jobs

16%

Employee Growth %

$36.8M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
GENEWIZ
$75.8M5196%
Hitachi Chemica...
$29.9M22919%
GENEWIZ
$75.8M5196%
Hitachi Chemica...
$29.9M22919%
Canfield Scient...
$29.3M2048%
Thomas Scientif...
$21.5M16720%
Canfield Scient...
$29.3M2048%
Thomas Scientif...
$21.5M16720%
L Oreal USA
N/A5227%
L Oreal USA
N/A5227%

Champions Oncology News

20-Mar-19 - Champions Oncology, Inc (CSBR) CEO Ronnie Morris on Q3 2019

Champions Oncology, Inc. (NASDAQ:CSBR) Q3 2019 Earnings Conference Call March 18, 2019 4:30 PM ET. Company Participants. Ronnie

4-Mar-19 - Champions Oncology (CSBR) Q3 Earnings: What's in Store?

Champions Oncology develops technology solutions and services to customize the development and use of oncology drugs. The company

20-Mar-19 - Tocqueville Asset Management LP Has $621000 Stake in Champions

Tocqueville Asset Management L.P. lessened its holdings in shares of Champions Oncology Inc (NASDAQ:CSBR) by 11.2% during the fourth

Champions Oncology Funding

DateAmountRoundLead InvestorsReference
2013-01-31$9.3MUndisclosedArticle
2015-03-13$14.0MUndisclosedNew Enterprise AssociatesArticle
2016-06-13$5.2MUndisclosedNational Securities CorporationArticle

Champions Oncology Executive Hires

DateNameTitleReference
2011-11-02Gary G. GemignaniEVP/CFOArticle
2014-01-07Angela DaviesChief Medical OfficerArticle
2014-03-05Ido Ben-ZviDir Bioinformatics/Machine LearningArticle
2018-05-02Amy WesaDir Immuno-Oncology ResearchArticle

Champions Oncology New Location/Offices

DateLocationReference
2017-03-17Rockville, MDArticle